Infinite Epigenetics agreed to acquire Tally Health, creating a broader platform for adult DNA methylation datasets, epigenetic diagnostics, and personalized healthspan interventions. The deal combines Infinite Epigenetics’ epigenetics tools with Tally Health’s data assets and diagnostic-oriented approach. For the epigenetics space, the move reinforces a shift toward “measurement-to-intervention” workflows, where biomarkers support decisioning and downstream programs are positioned for clinical and commercial scale. The acquisition also suggests continued consolidation among companies working to operationalize methylation signatures for risk stratification and monitoring beyond early discovery.